Theraclone Sciences Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Out of Business

Theraclone Sciences General Information

Description

Developer of therapeutic antibodies discovery platform intended to discover monoclonal antibodies. The company offers a comprehensive and right means to screen and identify rare antibodies produced naturally by human memory B cells in response to disease-causing agents, enabling medical practitioners to identify the rare antibodies produced by selected individuals to successfully ward off disease.

Contact Information

Formerly Known As
Spaltudaq
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 1124 Columbia Street
  • Suite 300
  • Seattle, WA 98104
  • United States
+1 (206)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Decision/Risk Analysis
Vertical(s)
Corporate Office
  • 1124 Columbia Street
  • Suite 300
  • Seattle, WA 98104
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Theraclone Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business Completed Out of Business
4. Later Stage VC (Series C) 30-Apr-2015 Completed Clinical Trials - Phase 3
3. Reverse Merger 02-Dec-2013 Cancelled Clinical Trials - General
2. Later Stage VC (Series B) 12-Aug-2013 $50M $54.8M Completed Clinical Trials - General
1. Early Stage VC (Series A) 24-Jan-2005 $4.77M $4.77M Completed Startup
To view Theraclone Sciences’s complete valuation and funding history, request access »

Theraclone Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B1
Series A1 4,225,734 $0.001000 $0.06 $1 $1 1x $1 6.48%
To view Theraclone Sciences’s complete cap table history, request access »

Theraclone Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic antibodies discovery platform intended to discover monoclonal antibodies. The company offers a
Drug Delivery
Seattle, WA
22 As of 2015

Pennington, NJ
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Theraclone Sciences Competitors (38)

One of Theraclone Sciences’s 38 competitors is Gennao, a Venture Capital-Backed company based in Pennington, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gennao Venture Capital-Backed Pennington, NJ
Entrada Therapeutics Formerly VC-backed Boston, MA
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Navrogen Venture Capital-Backed Cheyney, PA
Memo Therapeutics Formerly VC-backed Zurich, Switzerland
You’re viewing 5 of 38 competitors. Get the full list »

Theraclone Sciences Patents

Theraclone Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20140328797-A1 Human rhinovirus (hrv) antibodies Inactive 01-May-2013
AU-2014257289-A1 Compositions and methods for the therapy and diagnosis of influenza Inactive 22-Apr-2013
CA-2909802-A1 Compositions and methods for the therapy and diagnosis of influenza Inactive 22-Apr-2013
EP-2988781-A2 Compositions and methods for the therapy and diagnosis of influenza Inactive 22-Apr-2013
EP-2988781-A4 Compositions and methods for the therapy and diagnosis of influenza Inactive 22-Apr-2013 C07K16/108
To view Theraclone Sciences’s complete patent history, request access »

Theraclone Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Theraclone Sciences Investments (1)

Theraclone Sciences’s most recent deal was a Joint Venture with OncoResponse. The deal was made on 18-Aug-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OncoResponse 18-Aug-2015 Joint Venture Drug Discovery
To view Theraclone Sciences’s complete investments history, request access »

Theraclone Sciences FAQs

  • When was Theraclone Sciences founded?

    Theraclone Sciences was founded in 2005.

  • Where is Theraclone Sciences headquartered?

    Theraclone Sciences is headquartered in Seattle, WA.

  • What is the size of Theraclone Sciences?

    Theraclone Sciences has 22 total employees.

  • What industry is Theraclone Sciences in?

    Theraclone Sciences’s primary industry is Drug Delivery.

  • Is Theraclone Sciences a private or public company?

    Theraclone Sciences is a Private company.

  • What is Theraclone Sciences’s current revenue?

    The current revenue for Theraclone Sciences is .

  • How much funding has Theraclone Sciences raised over time?

    Theraclone Sciences has raised $59.2M.

  • Who are Theraclone Sciences’s competitors?

    Gennao, Entrada Therapeutics, Vedanta Biosciences, Navrogen, and Memo Therapeutics are some of the 38 competitors of Theraclone Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process